By integrating support directly into existing workflows and focusing on solutions that eliminate "shoulder time," manufacturers can significantly reduce delays and improve patient outcomes.
Growing up, my dad often shared the parable of a man searching for his keys under a streetlamp. A passerby offers to help and asks if he dropped his keys where he’s looking. No, the man replies, he dropped them in the darkness but is looking where there's light because he can actually see there.
My dad loved telling me that parable because a) like all dads everywhere he really loved parables, and b) I was always losing my stuff as a kid. Now that I’m older (and still sadly constantly losing my keys), I think about that proverb quite a bit: I see it often in the way that we as a healthcare industry try to help doctors and patients start and stay on the right treatment: we focus on what’s visible and measurable, but the real challenges often lie in the shadows.
It’s just plain hard, sometimes obscenely so, for doctors and patients to overcome all the dumb non-clinical obstacles that get in the way of treatment. This is even harder for provider-administered drugs. Manufacturers rightly focus on reducing the time and blockers to treatment, but frequently target the most visible and measurable fixes.
This makes sense: these teams historically had few compliant levers to improve the process. One such lever is benefit verification (BV) support, where speed is key. That meant going from three days to two days to one day to hours to potentially instantly. No doubt, this is a worthy goal; an instant response for the provider could make the medical side of the benefit resemble the instantaneous pharmacy benefit.
But zooming out, that reduction in time from BV request-for-help to BV answer represents just a small piece of a much bigger puzzle. Most of the time-consuming parts of the script-to-therapy journey live in different parts of the process.
Let’s break down the script-to-therapy journey for a healthcare organization (HCO):
This process takes ~20 days on average (though we’ve seen data for some classes of therapy where it’s more like 40-60 days!). As the chart below shows, the time is taken up by almost everything else besides the actual time to run the BV, including the “shoulder” activities of waiting for it to go from exiting one process to hitting the top of the queue for the next.
While reducing the raw BV processing time is beneficial — and measurable! — it doesn’t significantly impact the overall process. To make a meaningful difference, manufacturers must consider the entire process holistically and find ways to shrink the “shoulder” times where the prescription is sitting in a queue:
But how do we shrink that “shoulder” time? One rule-of-thumb: if the provider or their team have to constantly get out of their existing workflow and “pull” support from the manufacturer, it will not work. That just adds one more queue and handoff for the administrative team to manage. Instead, manufacturers have to find ways to help providers inside their existing workflow. By doing so, the manufacturer can help address the problem proactively — not just reducing the shoulder times but eliminating them altogether. That’s hard, because these solutions are not fully “in the light”; but they are solutions that address where the problems actually lie.
Syam Palakurthy is the Founder and CEO of SamaCare
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.